On 9 February 2018, the University of Parma hosted the official presentation of the results of the PulmoMed project, which has the goal of developing therapeutic products in the form of inhalable powder from a pulmonary drug delivery platform.
Innovative research and advanced technologies to revolutionise the system of administering vaccines and intervene on the treatment of degenerative lung diseases, which stems from the collaboration between public and private partners, with financial support from the Emilia–Romagna Region.
The working group consists of four institutional and three industrial partners. The four research centres of the Emilia-Romagna High Technology Network are responsible for the research phase and the validation of formulations. Chiesi Farmaceutici, Bormioli Rocco Pharma and IMA have made available to the project their competence to develop the inhalable powder, to design the inhaler and to develop the filling technology necessary to dose the powders in the capsule. In fact, the project has given birth to Minima, a bench–mounted capsule–filling machine designed by IMA Active.
Ruggero Bettini, Professor of Pharmaceutical Technology at the University of Parma, focused on one of the project’s greatest values: “We can define PulmoMed as a supply chain project, which has set up in a system companies and institutional entities, promoting employment and scientific progress in our Region”.